secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001171843-25-002841
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus presents HBV functional cure data from imdusiran combo; AB-101 safety at EASL 2025
--------------------------------------------------------------------------------

- In Phase 2a IM-PROVE II, imdusiran + VTP-300 + low-dose nivolumab led to 15.3% functional cure rate (2/13) in patients with baseline HBsAg <1000 IU/mL.
- 3 patients in nivolumab cohort achieved HBsAg loss and seroconversion at week 48.
- AB-101 Phase 1a/1b Part 3: 10mg once daily for 28 days well tolerated with PD-L1 receptor occupancy similar to healthy volunteers; no liver dysfunction.
- Across all imdusiran Phase 2a trials, 8 patients functionally cured, 7 with baseline HBsAg <1000 IU/mL.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325002841/0001171843-25-002841-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325002841/f8k_050725.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002841

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer